About SURGINEX
SURGINEX is a Healthcare company based in Seoul (South Korea) founded in 2020. An AI-based drug discovery platform is provided for bio-services. SURGINEX has raised $6.31 million across 1 funding round from investors including Laguna Investment, Kiwoom Investment and Partners Investment. Its chief executive, as recorded, is Sejun Kim. SURGINEX offers products and services including Customized Exosome, Gene Experiments, Molecular Biological Service, Histopathological Service, and Animal Experiments Service. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is Surginex Co., Ltd.
Company details
SURGINEX was established in 2020 in Seoul, South Korea, within the biotechnology sector. An AI-driven platform for drug discovery is offered, alongside a bio-platform supporting drug development, molecular biology experiments, animal testing, and clinical trials. Next-generation lipid nanoparticles for drug delivery are developed, as well as a gallstone-dissolving platform, the SURGI healer system, and SURGI liver technology for liver regeneration using processed stem cell secretions.
- Headquarters Seoul, South Korea
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website surginex.com
- Legal Name Surginex Co., Ltd.
- Total Equity Funding$6.31M (USD)
in 1 rounds
- Latest Funding Round$6.31M (USD), Series A
Mar 2024
- InvestorsLaguna Investment
& 5 more
Products & Services of SURGINEX
SURGINEX offers a comprehensive portfolio of products and services, including Customized Exosome, Gene Experiments, Molecular Biological Service, Histopathological Service, and Animal Experiments Service.
Tailored exosomes for targeted drug delivery applications.
Custom CRISPR/Cas9 designs for genetic research and therapy.
RNA and protein analysis for biological and pharmaceutical studies.
Tissue slide preparation and analysis for pathology research.
Provision of models for disease-specific animal testing.
Funding Insights of SURGINEX
SURGINEX has successfully raised a total of $6.31M through 1 strategic funding round. The most recent funding activity was a Series A round of $6.31 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.31M
- Total Rounds 1
- Last Round Series A — $6.31M
- First Round $6.31M
(Mar 2024)
- Investors Count 6
All 1 funding rounds of SURGINEX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $6.31M | Series A | – | Laguna Investment, Kiwoom Investment | – |
6 investors in total: 6 institutional.
Investors in SURGINEX
SURGINEX has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Laguna Investment, Kiwoom Investment and Partners Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Laguna Investment is engaged in venture capital funding for startups. | lagunai.com | Seoul, South Korea | ||
Investment services are offered by Kiwoom Investment in South Korea. | kiwoominvest.com | Seoul, South Korea | ||
PE firm investing in South Korea and the US | partnersi.co.kr | Seoul, South Korea | ||
Financial support is provided to ventures by Hana Ventures. | hanaventures.co.kr | Seoul, South Korea | ||
Sector-agnostic investments are pursued primarily in South Korea. | pvcc.co.kr | Seoul, South Korea | ||
| lski.co.kr |
Investor details for SURGINEX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SURGINEX
1 people are tracked at SURGINEX (1 in leadership).
| Name | Role | Group |
|---|---|---|
Sejun Kim | CEO | Leadership |
Complete people profiles for SURGINEX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SURGINEX
2 dated milestones of SURGINEX across 4 years, from founding to its latest funding, stage changes and deals.
- Founded SURGINEX is founded.
- Funding First funding round of $6.3M.
Web traffic of SURGINEX
The website of SURGINEX (surginex.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▲ 8.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Surginex
Complete news archive for SURGINEX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SURGINEX
SURGINEX was founded in 2020 and raised its 1st funding round 4 years after it was founded.
SURGINEX is headquartered in Seoul, South Korea.
Sejun Kim is the CEO of SURGINEX, as recorded in our data.
SURGINEX is a funded company, having raised a total of $6.31M across 1 funding round to date. The company's 1st funding round was a Series A of $6.31M, raised on Mar 2024.
SURGINEX was established in 2020 in Seoul, South Korea, within the biotechnology sector. An AI-driven platform for drug discovery is offered, alongside a bio-platform supporting drug development, molecular biology experiments, animal testing, and clinical trials. Next-generation lipid nanoparticles for drug delivery are developed, as well as a gallstone-dissolving platform, the SURGI healer system, and SURGI liver technology for liver regeneration using processed stem cell secretions.
SURGINEX offers Customized Exosome, Gene Experiments, Molecular Biological Service, Histopathological Service, and Animal Experiments Service.
SURGINEX has 6 investors. Key investors include Laguna Investment, Kiwoom Investment, Partners Investment, Hana Ventures, and POSCO Capital.
SURGINEX operates through Surginex Co., Ltd..